Trixeo Aerosphere 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0017 
Minor change in labelling or package leaflet not 
23/11/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/2521 
This was an application for a variation following a 
19/10/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
WS/2457/G 
This was an application for a group of variations 
31/08/2023 
SmPC 
The SmPC section 6.3 Annex II has been updated as 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.d.1.g - Change in the specification parameters 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
follows:  
Shelf-life 3 years 
Page 2/5 
 
 
 
 
 
 
 
 
 
PSUSA/10908
Periodic Safety Update EU Single assessment - 
06/07/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
formoterol fumarate dihydrate / glycopyrronium 
bromide / budesonide 
IG/1603/G 
This was an application for a group of variations. 
14/04/2023 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10908
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
formoterol fumarate dihydrate / glycopyrronium 
bromide / budesonide 
IG/1542 
B.III.1.a.1 - Submission of a new/updated or 
16/09/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
PSUSA/10908
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
formoterol fumarate dihydrate / glycopyrronium 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
bromide / budesonide 
IA/0008 
A.7 - Administrative change - Deletion of 
19/05/2022 
15/05/2023 
Annex II and 
manufacturing sites 
PL 
PSUSA/10908
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
formoterol fumarate dihydrate / glycopyrronium 
bromide / budesonide 
IB/0004/G 
This was an application for a group of variations. 
01/10/2021 
24/06/2022 
SmPC, 
B.II.e.5.b - Change in pack size of the finished 
product - Deletion of a pack size(s) 
B.II.g.5.b - Implementation of changes foreseen in 
an approved change management protocol - 
Requires further supporting data 
Labelling and 
PL 
IA/0006 
B.III.1.a.2 - Submission of a new/updated or 
22/09/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10908
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
/202012 
formoterol fumarate dihydrate / glycopyrronium 
bromide / budesonide 
IAIN/0001/G 
This was an application for a group of variations. 
17/02/2021 
24/06/2022 
SmPC, Annex 
II and PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 5/5 
 
 
 
 
 
 
 
